Current and Emerging Therapies in Peripheral T-cell Lymphoma: Focus on Pralatrexate

Thanyanan Reungwetwattana, Sylvia Jaramillo, Julian R. Molina
2011 Clinical Medicine Insights: Therapeutics  
Peripheral T-cell lymphomas (PTCL) represent about 12%-15% of non-Hodgkin lymphomas and are characterized for being a molecularly heterogenous group of diseases. The optimal treatment for PTCLs remains to be defined as they are usually refractory to existing therapies and carry a poor prognosis. Pralatrexate (PDX), a rationally designed antifolate drug, was granted FDA approval as a single agent for the treatment of relapsed/refractory PTCL in 2009. Because of its favorable toxicity profile and
more » ... oxicity profile and activity, Pralatrexate has become a major compound for patients with refractory PTCL.
doi:10.4137/cmt.s3778 fatcat:ipftrlwtobfbnkt2qtey623zsi